NCT06843551
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Recruiting
PHASE2Ages 18+InterventionalTreatmentBenjamin SpielerInvestigator-initiated
~20 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:Stereotactic Body Radiation TherapyBotensilimabBalstilimab
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical Benefit Rate (CBR)
Measured over Up to 15 months
Conditions
NCT06843551
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Miami
Miami, Floridastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Benjamin Spieler, MD · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Clinical Benefit Rate (CBR)Up to 15 months
The Clinical Benefit Rate (CBR) among participants will be reported. CBR is the number of participants achieving complete response (CR), partial response (PR) or stable disease after start of study therapy. Response will be assessed using Immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) 1.1 criteria.